Edwards Lifesciences Corporation $EW Shares Purchased by Tobam

Tobam raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 27.7% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 85,646 shares of the medical research company’s stock after purchasing an additional 18,590 shares during the period. Edwards Lifesciences makes up approximately 1.8% of Tobam’s investment portfolio, making the stock its 12th biggest position. Tobam’s holdings in Edwards Lifesciences were worth $7,301,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of EW. Washington Trust Advisors Inc. grew its position in shares of Edwards Lifesciences by 15.6% during the third quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock worth $10,156,000 after buying an additional 17,625 shares in the last quarter. Elo Mutual Pension Insurance Co raised its holdings in Edwards Lifesciences by 39.9% in the third quarter. Elo Mutual Pension Insurance Co now owns 89,674 shares of the medical research company’s stock valued at $6,974,000 after acquiring an additional 25,562 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Edwards Lifesciences by 27.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after acquiring an additional 23,514 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Edwards Lifesciences by 39.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock valued at $194,907,000 after acquiring an additional 648,870 shares during the last quarter. Finally, Central Pacific Bank Trust Division acquired a new position in Edwards Lifesciences during the 4th quarter worth $775,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 81,038 shares of company stock valued at $6,683,255 over the last three months. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $87.51 on Friday. The company has a market cap of $50.39 billion, a P/E ratio of 46.55, a PEG ratio of 2.19 and a beta of 0.87. The business has a 50 day moving average of $83.39 and a two-hundred day moving average of $83.14. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $89.60. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EW. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price for the company in a research report on Wednesday, April 1st. Evercore reaffirmed an “outperform” rating and set a $93.00 price target on shares of Edwards Lifesciences in a research report on Friday, April 24th. Barclays reissued an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Truist Financial set a $90.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Finally, Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $95.96.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.